India’s Drug controller general of India(DCGI) gives permission to Bharat Biotech for Phase -3 clinical trials after completion of Phase -1 and Phase 2 trials of COVAXIN. The phase-3 clinical trials will be done in 25 centre in 26,000 participants across India.
